ClinicalTrials.gg
CompletedNCT00909025Updated Nov 21, 2024

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

A Phase 1 interventional study of Claudiximab in Solid Tumors, sponsored by Ganymed Pharmaceuticals GmbH. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Ganymed Pharmaceuticals GmbH (part of Astellas Pharma Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of this phase I study is to establish safety, toxicity and maximal tolerable dose of a single infusion of claudiximab in patients suffering from relapsing, advanced gastroesophageal and gastric adenocarcinoma

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Ganymed Pharmaceuticals GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Ganymed Pharmaceuticals GmbH became part of Astellas Pharma Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , or recurrent disease of advanced gastroesophageal cancer (adenocarcinoma) proven by histology
  • CLDN18.2 expression confirmed by immunohistochemistry
  • Prior standard chemotherapy containing a fluoropyrimidine, a platinum compound and/or epirubicine, and - if clinically appropriate - docetaxel
  • At least 1 measurable site of the disease according criteria (CT-scans or MRT not older than 6 weeks before study entry)
  • Age ≥ 18 years
  • performance status (PS) 0-1 or Index 70-100%
  • > 3 months
  • count ≥ 100,000/mm³
  • ≥ 10 g/dl
  • \< 1.5
  • normal
  • and ALT \< 2.5 times (ULN) (5 times ULN if liver metastases are present)
  • Creatinine \< 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Prior allergic reaction or intolerance to a monoclonal antibody
  • Prior inclusion in the present study
  • Less than 3 weeks since prior anti-tumor or radiation therapy
  • Other agents or devices concurrently or within 4 weeks prior to this study
  • Other concurrent anticancer therapies
  • History of positive test for (HIV) antibody
  • Known Hepatitis.
  • Uncontrolled or severe illness.
  • Concurrent administration of anticoagulation agents with vitamin K antagonists
  • Concurrent administration of therapeutic doses of heparin (prophylactic doses are acceptable)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Claudiximab

    Drug: Claudiximab

Interventions

  • Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT. After completion of study treatment, patients are followed for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Determination of maximum tolerated dose of claudiximab (Phase I: toxicities as assessed by NCI CTCAE version 3.0)

    Time frame: Four weeks

Secondary outcomes

  1. Determination of the safety profile

    Time frame: Four weeks

  2. Pharmacokinetic evaluation

    Time frame: Four weeks

  3. Overall tumor response as assessed by RECIST

    Time frame: Four weeks

  4. Evaluation of immunogenicity

    Time frame: Four weeks

  5. Determination of antitumoral efficacy

    Time frame: Four weeks

07

Study locations

6 sites
  • Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
    Essen, 45122, Germany
  • Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
    Heidelberg, 69120, Germany
  • Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik
    Mainz, 55131, Germany
  • Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik
    München, 81674, Germany
  • Piejuras Hospital
    Liepaja, 3401, Latvia
  • Pauls Stradins University
    Riga, 1002, Latvia
08

References and documents

Publications

  • Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, Huber C, Tureci O. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 Sep;100:17-26. doi: 10.1016/j.ejca.2018.05.007. Epub 2018 Jun 21. PubMed 29936063 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2009 to primary completion in May 2010, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2009
First posted
May 27, 2009
StartActual
May 31, 2009
Primary completionActual
May 31, 2010
CompletionActual
May 31, 2010
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00909025
Responsible party
Sponsor
First posted
May 27, 2009
Start date
May 31, 2009
Primary completion
May 31, 2010
Completion
May 31, 2010
Last update
Nov 21, 2024

Study contacts

Martin Schuler, Prof.Dr.med.
principal investigator · Innere Klinik (Tumorforschung) Universitätsklinikum Essen Hufelandstr. 55 45122 Essen, GERMANY

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion